Targeted therapy for hormone receptor-positive breast cancer
- Medical Review: Sameer Gupta, MD, MPH, Pallav K. Mehta, MD
Hormone receptor-positive breast cancers grow in response to the hormones estrogen and progesterone. These cancers are often treated with hormonal therapy medicines.
Hormonal therapy medicines can work in two ways. They either stop the body from making estrogen or they block the effects of estrogen that drive cancer growth.
Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help those cells grow. There are many different kinds of targeted therapy. Hormonal therapy is actually a type of targeted therapy because it targets hormones that are active in cancer growth. Hormonal therapy has been used to treat breast cancer for many years. But doctors are now using newer kinds of targeted therapy to treat hormone receptor-positive breast cancer as well.
Over time, some breast cancers can build resistance to hormonal therapies. Studies have shown that some hormonal therapies are more effective when combined with other targeted therapies. Your doctor may recommend a combination therapy as first-line treatment or later on, if the cancer stops responding to hormonal therapy.
The FDA has approved four kinds of targeted therapy to treat hormone receptor-positive breast cancer: AKT inhibitors, CDK 4/6 inhibitors, mTOR inhibitors, and PI3K inhibitors.
These targeted therapy medicines are mostly used to treat advanced or metastatic breast cancers; one CDK 4/6 inhibitor is also approved for early-stage breast cancer that has spread to the lymph nodes.
If you have hormone receptor-positive breast cancer and are interested in targeted therapies, ask your doctor whether these medicines are an option for you. If they are not, ask if you might be able to participate in a clinical trial.
Targeted therapies, hormonal therapies, and chemotherapy all cause different kinds of side effects. They can vary in type and level of disruption and seriousness. What happens to one person may not happen to you. Talk with your health care team about possible side effects to learn how you can prevent or lessen them, and check out our Side effects page for tips on how to cope.
AKT inhibitors
AKT inhibitors target the AKT protein, which helps regulate cell growth, division, and survival. To do this, the AKT protein sends signals to PIK3CA and PTEN proteins within the PIK3-AKT pathway, a chain of molecules that acts as a communication network inside a cell. There is one FDA-approved AKT inhibitor, capivasertib (Truqap). Capivasertib stops AKT from working. Capivasertib is taken with fulvestrant (Faslodex).
Capivasertib is approved for people living with hormone receptor-positive, HER2-negative metastatic breast cancer that tests positive for AKT1, PIK3CA, or PTEN mutations, after the breast cancer grows or spreads while on an endocrine therapy.
Capivasertib is also approved for people who have a hormone receptor-positive, metastatic breast cancer diagnosis during or within 12 months of completing treatment for early-stage breast cancer. The cancer must test positive for AKT1, PIK3CA, or PTEN mutations.
In the phase III CAPItello-291 clinical trial, capivasertib plus fulvestrant lowered the risk of progression or death by 50% in people diagnosed with locally advanced or metastatic hormone receptor-positive breast cancer that had AKT pathway mutations when compared with fulvestrant alone. In the overall study population, the risk was lowered by 40%.
Capivasertib side effects include rash, diarrhea, increased blood sugar levels, nausea or vomiting, fatigue, high triglycerides, higher levels of creatinine, low blood cell counts, and mouth sores.
Learn more about this medicine and testing requirements on the capivasertib page.
CDK 4/6 inhibitors
CDK 4/6 inhibitors, also called cyclin-dependent kinase 4/6 inhibitors, target two specific kinases, CDK 4 and 6. These kinases, or proteins, signal cancer cells to grow and divide. Blocking these proteins in hormone receptor-positive breast cancer cells helps stop the cells from growing and spreading.
Three CDK 4/6 inhibitors are approved to treat hormone receptor-positive, HER2-negative breast cancer. The three CDK 4/6 inhibitors are:
Who can take CDK 4/6 inhibitors and how they are used
For people diagnosed with hormone receptor-positive, HER2-negative early-stage breast cancer, there are two FDA-approved CDK 4/6 inhibitors:
- Abemaciclib, in combination with an aromatase inhibitor or tamoxifen, is approved for use after surgery to treat early-stage hormone receptor-positive, HER2-negative breast cancer that has traveled to the lymph nodes and has a high risk of recurrence.
- Ribociclib, in combination with an aromatase inhibitor, is approved for use after surgery to treat hormone receptor-positive, HER2-negative stage II and stage III early breast cancer that has a high risk of recurrence.
For people diagnosed with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer:
- All three CDK 4/6 inhibitors—abemaciclib, palbociclib, and ribociclib—are approved as a first treatment in combination with hormonal therapy.
- Several clinical trials have shown that these treatments can help people live without metastatic cancer progression for several months to a year longer than hormonal therapy alone.
CDK 4/6 inhibitors are taken as pills, typically once or twice a day.
In advanced or metastatic breast cancer, CDK 4/6 inhibitors can be given as a first treatment, or it can be given later.
As first-line therapy (a first treatment after diagnosis of advanced or metastatic breast cancer), any of these three medicines can be given along with an aromatase inhibitor or fulvestrant to women who have gone through menopause, or to men.
- Palbociclib and abemaciclib, combined with fulvestrant, may be used for people whose cancer progressed on hormonal therapy and had one line of chemotherapy or no chemotherapy at all. Ribociclib also may be used in this way for postmenopausal women and men.
- Abemaciclib can also be used by itself in people who have previously been treated with hormonal therapy and chemotherapy.
Pre- and perimenopausal women taking a CDK 4/6 inhibitor plus an aromatase inhibitor or fulvestrant must also take a gonadotropin-releasing hormone (GnRH) agonist. GnRH agonists stop the ovaries from producing estrogen. Men are also usually advised to take a GnRH agonist to lower testosterone levels in the body.
What’s similar and different among the CDK 4/6 inhibitors
All three CDK 4/6 inhibitors are taken by mouth, as pills.
In early breast cancer:
- Abemaciclib is taken twice a day for two years.
- Ribociclib is taken once a day for 21 days, followed by a seven-day break, for three years.
In advanced and metastatic breast cancer:
- Abemaciclib is taken twice a day. In some people, abemaciclib can be used alone, without any hormonal therapy, for metastatic breast cancer.
- Ribociclib and palbociclib are taken once a day for 21-day cycles followed by a seven-day break.
These medicines are not recommended for women who are pregnant or may become pregnant. They also may cause fertility problems in men. CDK 4/6 inhibitors should not be taken with strong doses of medications that affect the enzyme known as CYP3A, as well as grapefruit or grapefruit juice.
CDK 4/6 inhibitors have similar side effects, the most common being neutropenia and leukopenia (decreases in white blood cell counts). These can increase the risk of illness and infection.
Other shared side effects can include fatigue, nausea and vomiting, mouth sores, hair loss, diarrhea, and headache.
Abemaciclib causes diarrhea more frequently than the other two drugs, and in some people, it can be severe and lead to dehydration. This medicine also can cause uncommon but serious side effects such as:
- Inflammation of the lungs
- Liver problems
- Blood clots in the veins or in the arteries of the lungs
Ribociclib also can lead to uncommon but potentially serious side effects such as:
- Inflammation of the lungs
- Severe skin reactions
- QT interval prolongation, a heart rhythm problem that can lead to a fast or irregular heartbeat
- Liver problems
Your doctor will monitor you for side effects and tell you what symptoms to watch for. If you experience a severe side effect, the dosage of the medication can be reduced as needed. In fact, the prescribing information for each medication has specific instructions about how to reduce the dosage to lessen side effects. Your doctor also can recommend strategies for preventing infection and managing diarrhea.
Choosing a CDK 4/6 inhibitor
Your doctor can help you decide which CDK 4/6 inhibitor to take, based on the features of the cancer, your menopausal status, and which treatments you have already had, if any. Other factors in that decision may include:
- Side effects: Your medical history or personal preferences may lead you and your doctors to avoid a certain CDK 4/6 inhibitor based on side effects—such as the potential for severe diarrhea, or liver or heart rhythm problems.
- Ease of access/health insurance coverage: Insurance coverage for CDK 4/6 inhibitors can vary depending on the plan you have. In addition, if your doctors need to reduce the dose because of side effects, certain CDK 4/6 inhibitors require a new prescription, versus simply taking one fewer pill. This may influence your decision.
- Your doctor’s preference: If your team tends to use one of these medicines more than others in a specific situation or certain groups of patients, this may affect their recommendations.
Because these medicines have shown similar effectiveness for controlling breast cancer in clinical trials so far, you and your doctors can make the choice that is right for you.
Switching between CDK 4/6 inhibitors
If you experience difficult side effects that do not improve when the dose of a CDK 4/6 inhibitor is lowered, your doctors may recommend switching to a different one.
If you have been diagnosed with metastatic breast cancer that progresses while on CDK 4/6 inhibitor therapy, there is not enough evidence yet to suggest that a different CDK 4/6-containing regimen will be effective. However, your doctor still may recommend trying a different CDK 4/6 inhibitor. Other options may include:
- Using fulvestrant alone, or combining it with another targeted therapy called alpelisib (Piqray), if the cancer has a PIK3CA mutation (apelisib is a PI3K inhibitor)
- Using the mTOR inhibitor everolimus (Afinitor) with exemestane (Aromasin), a hormonal therapy medicine
The choice often depends on whether or not the cancer responded well to hormonal therapy in the past. Your doctor can help you decide based on your individual situation.
Generally, doctors will use targeted therapies before recommending chemotherapy, unless the cancer is causing difficult symptoms—such as pain or trouble breathing—related to where it has moved within the body.
Research on CDK 4/6 inhibitors
Researchers continue to study how best to use CDK 4/6 inhibitors. Some key questions they are trying to answer include:
- Are there certain tumor biomarkers (such as specific gene mutations) that make a cancer more likely to respond to a CDK 4/6 inhibitor?
- In metastatic breast cancer, should a CDK 4/6 inhibitor be continued if the cancer progresses, or should it be switched?
- Do CDK 4/6 inhibitors work well in combination with other therapies besides hormonal therapy?
- Can these medicines be used in HER2-positive cancer?
More specifically, some clinical trials are looking at:
- Using abemaciclib after breast cancer progresses on palbociclib
- Using either fulvestrant or fulvestrant plus ribociclib in people with metastatic breast cancer that progresses on palbociclib or ribociclib plus an aromatase inhibitor
- Combining an investigational CDK 4/6 inhibitor, dalpiciclib, with an aromatase inhibitor and comparing its effectiveness to chemotherapy alone
- Combining paclitaxel with palbociclib in people with different subtypes of breast cancer who have not had a CDK 4/6 inhibitor before
The use of these medicines is likely to be updated as new clinical trial results become available in the coming years. To learn more about accessing these options, explore the resources in Clinical trials.
mTor inhibitors
mTOR, or mammalian target of rapamycin, is a type of protein called a kinase. Kinase helps control cell growth.
In some cancers, mTOR-activated proteins work abnormally and encourage cancer cells to grow and spread. mTOR also directs nutrients to the cancer cells, helping to support them.
mTOR inhibitors are a newer type of targeted therapy. They work to slow or stop mTOR’s role in the growth of cancer cells. The mTOR inhibitor approved to treat metastatic breast cancer is:
PI3K inhibitors
PI3K, also called phosphatidylinositol-3 kinase, is a family of enzymes that control cell growth. If breast cancer has a mutation in a gene called PIK3CA, PI3K can become overactive, causing cancer cells to grow. PI3K inhibitors are medicines that block this process. Two PI3K inhibitors are approved to treat hormone receptor-positive, HER2-negative, PIK3CA mutation-positive advanced or metastatic breast cancer:
Antibody-drug conjugates
Antibody-drug conjugates (ADCs) are treatments that pair a chemotherapy medicine with a targeted therapy. There is one ADC approved to treat hormone receptor-positive breast cancer:
- Sacituzumab govitecan (Trodelvy) is approved to treat metastatic breast cancer that is hormone receptor-positive and HER2-negative. It is also approved to treat metastatic breast cancer that is triple-negative.
This content is supported by
Related news
- Imlunestrant proves effective against hormone receptor-positive, HER2-negative advanced breast cancer | SABCS 2024
- Enfortumab vedotin shows anti-tumor activity but does not meet trial goals | ASCO 2024
- Abemaciclib shows small benefit after a prior CDK 4/6 inhibitor stops working | ASCO 2024
- Trastuzumab deruxtecan beats chemotherapy—even in HER2-ultralow MBC | ASCO 2024
Related videos
View moreStay connected
Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.
Reviewed and updated: October 14, 2024
Reviewed by: Sameer Gupta, MD, MPH , Pallav K. Mehta, MD
Tagged:
- 3-dimensional radiation therapy
- 4-hydroxytamoxifen
- ablation
- abnormal
- Abraxane
- absolute risk
- AC regimen
- AC-T regimen
- AC-T-T regimen
- AC-Taxol regimen
- AC-TH regimen
- accelerated partial-breast irradiation
- action study
- acupoint
- acupressure
- acupuncture
- acupuncture needle
- acupuncture point
- acupuncture point injection
- acupuncturist
- acustimulation
- acute
- acute pain
- adenocarcinoma
- adenopathy
- adenosis
- adjunct agent
- adjunct therapy
- adjunctive therapy
- adjuvant therapy
- advance directive
- advanced practice nurse
- adverse effect
- aerobic exercise
- agent study
- aggravating factor
- aggressive
- AJCC staging system
- Alkeran
- alkylating agent
- Allegra
- allopathic medicine
- alopecia
- amifostine
- aminoglutethimide
- amitriptyline
- anabolic steroid
- analgesic
- anaplastic
- anastrozole
- ancillary test
- anemia
- anesthesia
- anesthesiologist
- angiogenesis
- angiogenesis inhibitor
- antagonist
- anthracycline
- anti-anxiety medicine
- anti-idiotype vaccine
- anti-inflammatory
- antibody-dependent cellular cytotoxicity
- antibody therapy
- anticachexia
- anticancer antibiotic
- anticancer therapy
- anticonvulsant
- antidepressant
- antiemetic
- antiestrogen
- antifolate
- antigen-presenting cell vaccine
- antihormone therapy
- antimetabolite
- antimitotic agent
- antineoplastic
- antitumor
- anxiety
- anxiolytic
- Anzemet
- APN
- apocrine gland
- apoptosis
- aprepitant
- areola
- Aromasin
- aromatase inhibitor
- aromatherapy
- arthralgia
- ascites
- aspirate
- aspiration
- assay
- asthenia
- asymptomatic
- atypia
- atypical ductal hyperplasia
- atypical hyperplasia
- atypical lobular hyperplasia
- avoidance
- axillary lymph node
- axillary lymph node dissection
- BAK gel
- balloon catheter radiation
- baseline
- behavior modification
- best practice
- BI-RADS
- Biafine cream
- bias
- bilateral
- bilateral breast cancer
- bilateral prophylactic mastectomy
- bilateral salpingo-oophorectomy
- biofeedback
- biologic
- biopsy
- biopsy specimen
- biotherapy
- bisphosphonate
- bisphosphonate-associated osteonecrosis
- blinded study
- blood-brain barrier
- blood-brain barrier disruption
- blood cell count
- blood chemistry study
- board certified oncology pharmacy specialist
- body image
- body mass index
- bolus dose
- bone density
- bone metastasis
- bone mineral density scan
- bone scan
- bone-seeking radioisotope
- brachytherapy
- brain metastasis
- BRCA1
- BRCA2
- BRCAPro
- breast carcinoma in situ
- breast-conserving surgery
- breast density
- breast duct
- breast duct endoscopy
- breast lobe
- breast lobule
- breast reconstruction
- breast self-exam
- Brief Pain Inventory
- cachexia
- CAF regimen
- calcification
- cancer vaccine
- candidiasis
- capecitabine
- carboplatin
- carcinogen
- carcinoma
- carcinoma in situ
- carcinomatous meningitis
- carcinosis
- carcinostatic
- cardiotoxicity
- caregiver
- carmustine
- case-control study
- case report
- case series
- CAT scan
- CBC
- cell
- cell-cycle regulation
- cell proliferation
- central nervous system
- central nervous system metastasis
- central nervous system prophylaxis
- central venous access catheter
- cetuximab
- cevimeline
- chaplain
- charged-particle radiation therapy
- chemoembolization
- chemoimmunotherapy
- chemoprevention
- chemoprevention study
- chemoprotective
- chemoradiation
- chemosensitivity
- chemosensitivity assay
- chemosensitizer
- chemotherapeutic agent
- chemotherapy
- chest wall
- chest X-ray
- Chinese meridian theory
- chronic
- chronic pain
- cisplatin
- Claus model
- clergy
- clinical
- clinical breast exam
- clinical practice guidelines
- clinical researcher
- clinical resistance
- clinical series
- clinical stage
- clinical staging
- clinical study
- clinical trial
- clinician
- clodronate
- CMF regimen
- cognition
- cognitive behavior therapy
- cognitive therapy
- cohort
- cohort study
- coinsurance
- combination chemotherapy
- comedo carcinoma
- comfort care
- Coming Out
- Community Advisory Board
- comorbidity
- compassionate use trial
- complementary and alternative medicine
- complementary medicine
- complete metastasectomy
- complete remission
- complete response
- complex decongestive therapy
- compliance
- complication
- compression garment
- computed tomography scan
- concomitant
- concurrent therapy
- condition
- consolidation therapy
- constitutional acupuncture
- continuum of care
- contract research organization
- contraindication
- contralateral
- contrast material
- control group
- controlled clinical trial
- controlled study
- conventional medicine
- conventional therapy
- copayments
- cope
- coping skills
- core biopsy
- core needle biopsy
- corticosteroid
- counseling
- COX inhibitor
- cryoablation
- cryopreservation
- cryosurgery
- CT scan
- cultural competency
- cumulative dose
- cumulative exposure
- cure
- cutaneous
- cutaneous breast cancer
- cyclophosphamide
- cyclosporine
- CYP2D6 inhibitor
- cystosarcoma phyllodes
- cytopenia
- cytotoxic
- cytotoxic chemotherapy
- Cytoxan
- Data and Safety Monitoring Board
- DCIS
- de novo
- debulking
- deductible
- definitive surgery
- definitive treatment
- dehydration
- denosumab
- depression
- diagnosis
- diagnostic mammogram
- diagnostic procedure
- diagnostic technique
- diagnostic trial
- diameter
- diarrhea
- diaziquone
- DIEP flap
- dietary counseling
- dietary supplement
- dietitian
- differentiation
- diffuse
- digital mammography
- diphenhydramine
- discharge
- disease progression
- disease-specific survival rate
- distant cancer
- distant metastasis
- Distant recurrence
- distress
- DNR order
- docetaxel
- dolasetron
- dose
- dose-dense chemotherapy
- dose-dependent
- dose-limiting
- dose-rate
- double-blinded
- doxorubicin
- drain
- dronabinol
- droperidol
- drug interaction
- drug resistance
- drug therapy
- drug tolerance
- duct
- ductal carcinoma
- ductal carcinoma in situ
- ductal lavage
- duloxetine
- durable power of attorney
- dysfunction
- dysgeusia
- dyspepsia
- dyspnea
- early menopause
- early-stage breast cancer
- edema
- EEG biofeedback
- efficacy
- Eklund displacement views
- electroacupuncture
- electron beam
- eligibility criteria
- Ellence
- emesis
- emetic
- endocrine
- endocrine therapy
- endpoint
- energy healing
- enteral nutrition
- epidemiology
- epirubicin
- ER+
- ER-
- ER
- ER-PR-HER2/neu-
- eribulin mesylate
- erythema
- estradiol
- estrogen
- estrogen blocker
- estrogen receptor
- estrogen receptor-negative
- estrogen receptor-positive
- estrogen receptor test
- estrogen replacement therapy
- etanidazole
- etidronate
- everolimus
- Evista
- excision
- excisional biopsy
- exemestane
- expanded access trial
- experimental
- extranodal
- false-negative test result
- false-positive test result
- familial cancer
- family medical history
- Faslodex
- fast-neutron beam radiation
- fatigue
- FDA
- febrile neutropenia
- FEC regimen
- Femara
- fertility
- fexofenadine
- fibroadenoma
- fibrocystic breast changes
- fiducial marker
- film mammography
- fine-needle aspiration biopsy
- first-degree relative
- first-line therapy
- five-year survival rate
- fluorouracil
- fluoxetine
- FNA biopsy
- focal
- Food and Drug Administration
- Fosamax
- fractionation
- fulvestrant
- functional magnetic resonance imaging
- gadolinium
- Gail model
- gallium scan
- gamma irradiation
- Gamma Knife therapy
- gamma ray
- Gelclair
- gemcitabine
- gene
- gene expression profile
- gene therapy
- general anesthesia
- generalized anxiety disorder
- generic
- genetic
- genetic counseling
- genetic marker
- genetic marker of susceptibility
- genetic predisposition
- genetic profile
- genetic susceptibility
- genetic testing
- genetic testing
- genetics
- genome
- genome-wide association study
- genomic profile
- genomic test
- genomics
- gland
- Good Clinical Practice
- goserelin
- grade
- grading
- granisetron
- gross description
- Halaven
- hazard ratio
- healing touch
- Health Insurance Portability and Accountability Act
- healthcare provider
- healthcare proxy
- healthy control
- helical computed tomography
- HER2/neu
- Herceptin
- hereditary
- hereditary mutation
- heteronormative
- high-dose chemotherapy
- high-dose radiation
- high-energy proton therapy
- high grade
- high-risk cancer
- HIPPA
- histologic examination
- histology
- historic cohort study
- historical control subject
- homeopathic medicine
- hormonal therapy
- hormone
- hormone receptor
- hormone receptor test
- hormone replacement therapy
- hormone responsive
- hormone therapy
- hospice
- hot flash
- human epidermal growth factor receptor 2
- human participant protection regulations
- hydroxydaunorubicin
- hyperalimentation
- hypercalcemia
- hyperfractionated radiation therapy
- hyperfractionation
- hyperplasia
- hypersensitivity
- hypofractionated radiation therapy
- hypofractionation
- hypoxia
- ibandronate
- ibuprofen
- idiopathic
- image-guided radiation therapy
- imaging
- imaging procedure
- immune adjuvant
- immune function
- immune response
- immune system
- immune system tolerance
- immunization
- immunoassay
- immunocompromised
- immunodeficiency
- immunohistochemistry
- immunology
- immunomodulation
- immunosuppression
- immunotherapy
- implant
- implant displacement views
- implant radiation therapy
- implantable pump
- in network
- in situ
- incidence
- incision
- incisional biopsy
- indication
- indolent
- induction therapy
- infection
- infertile
- infertility
- infiltrating breast cancer
- infiltrating ductal carcinoma
- inflammation
- inflammatory breast cancer
- informed consent
- infusion
- ingestion
- inherited
- iniparib
- injection
- inoperable
- insomnia
- Institutional Review Board
- intensification therapy
- intensity-modulated radiation therapy
- interfering thought
- internal mammary lymph nodes
- internal radiation therapy
- International Unit
- internist
- interstitial radiation therapy
- intervention
- intervention group
- intra-arterial
- intracarotid infusion
- intradermal
- intraductal breast papilloma
- intraductal carcinoma
- intrahepatic
- intrahepatic infusion
- intramuscular
- intramuscular injection
- intraoperative radiation therapy
- intraoperative ultrasound
- intratumoral
- intravasation
- intravenous
- intravenous infusion
- intravenous injection
- intrusive thought
- intrusive thoughts
- invasive breast cancer
- invasive cancer
- invasive procedure
- investigational
- investigator
- ionizing radiation
- ipsilateral
- IRB
- irradiated
- irradiation
- irreversible toxicity
- ixabepilone
- joint pain
- Karnofsky Performance Status
- laboratory test
- lapatinib
- laser
- laser surgery
- laser therapy
- lassitude
- late effects
- late-stage cancer
- latent
- laxative
- LEEP
- legal aid organization
- lesion
- lethargy
- letrozole
- leukopenia
- levels of evidence
- Lexapro
- libido
- lidocaine
- ligation
- linac
- linear accelerator
- lipoma
- lisofylline
- liver metastasis
- liver scan
- living will
- lobaplatin
- lobe
- lobectomy
- lobular carcinoma
- lobular carcinoma in situ
- lobule
- local anesthesia
- local cancer
- local therapy
- localization
- localized
- locally advanced cancer
- locally recurrent cancer
- lomustine
- loop electrosurgical excision procedure
- loop excision
- lorazepam
- low grade
- lubricant
- lumbar puncture
- lumpectomy
- lung metastasis
- luteinizing hormone-releasing hormone agonist
- lymph
- lymph gland
- lymph node
- lymph node dissection
- lymph node drainage
- lymph node mapping
- lymph vessel
- lymphadenectomy
- lymphadenopathy
- lymphangiogram
- lymphangiography
- lymphatic basin
- lymphatic fluid
- lymphatic mapping
- lymphatic system
- lymphatic vessel
- lymphedema
- lymphography
- lymphoscintigraphy
- Lyrica
- lytic lesion
- macrocalcification
- magnetic resonance imaging
- magnetic resonance perfusion imaging
- magnetic resonance spectroscopic imaging
- mainstream medicine
- maintenance therapy
- male breast cancer
- malignancy
- malignant
- malignant pleural effusion
- malnutrition
- mammary
- mammary dysplasia
- mammary gland
- mammogram
- mammography
- MammoSite
- Mammotome
- mantle field
- MAO inhibitor
- margin
- marker
- mass
- massage therapy
- mastectomy
- mastitis
- maternal
- maximum tolerated dose
- mean survival time
- measurable disease
- medial supraclavicular lymph node
- median
- median survival time
- Medicaid
- medical castration
- medical device
- medical nutrition therapy
- medical oncologist
- Medicare
- medicine
- medullary breast carcinoma
- mega-voltage linear accelerator
- megestrol
- melphalan
- meningeal metastasis
- menopause
- menorrhagia
- menstrual cycle
- menstrual period
- menstruation
- mental health
- mental health counselor
- meridian
- mesna
- meta-analysis
- metallic
- metastasectomy
- metastasis
- metastasize
- metastatic
- methotrexate
- metoclopramide
- metronomic therapy
- microcalcification
- micrometastasis
- microscopic
- milk duct
- mind/body exercise
- mindfulness relaxation
- Miraluma test
- mitigate
- modified radical mastectomy
- molecular marker
- molecular medicine
- molecular risk assessment
- molecularly targeted therapy
- monoamine oxidase inhibitor
- monoclonal antibody
- morbidity
- mortality
- MRI
- MRSI
- MTD
- mTOR
- mucositis
- multicenter study
- multicentric breast cancer
- multidisciplinary
- multidisciplinary opinion
- multidrug resistance
- multidrug resistance inhibition
- multifocal breast cancer
- music therapy
- mutation
- mutation carrier
- myalgia
- myelosuppression
- nanoparticle paclitaxel
- narcotic
- National Cancer Institute
- National Center for Complementary and Alternative Medicine
- National Institutes of Health
- natural history study
- naturopathy
- nausea
- NCCAM
- NCI
- NCI clinical trials cooperative group
- needle biopsy
- needle localization
- needle-localized biopsy
- negative axillary lymph node
- negative test result
- neoadjuvant therapy
- neoplasm
- nerve
- nerve block
- neurocognitive
- neurologic
- neuropathy
- neurotoxicity
- neurotoxin
- neutropenia
- NIH
- nipple
- nipple discharge
- nitrosourea
- NMRI
- node-negative
- node-positive
- nodule
- nonblinded
- nonconsecutive case series
- noninvasive
- nonmalignant
- nonmetastatic
- nonprescription
- nonrandomized clinical trial
- nonsteroidal anti-inflammatory drug
- nonsteroidal aromatase inhibitor
- nontoxic
- normal range
- normative
- NP
- NPO
- NSAID
- nuclear grade
- nuclear magnetic resonance imaging
- nuclear medicine scan
- nurse
- nurse practitioner
- nutrition
- nutrition therapy
- nutritional counseling
- nutritional status
- nutritional supplement
- nutritionist
- obese
- objective improvement
- objective response
- observation
- observational study
- obstruction
- off-label
- olaparib
- oncologist
- oncology
- oncology nurse
- oncology pharmacy specialist
- oncolysis
- ondansetron
- onset of action
- oophorectomy
- open biopsy
- open label study
- open resection
- operable
- opiate
- opioid
- opportunistic infection
- oral
- organ
- orthodox medicine
- osteolytic
- osteonecrosis of the jaw
- osteopenia
- osteoporosis
- OTC
- out of network
- outcome
- outpatient
- ovarian
- ovarian ablation
- ovarian cancer
- ovarian suppression
- ovary
- over-the-counter
- overall survival rate
- overdose
- overexpress
- overweight
- ovulation
- PA
- paclitaxel
- paclitaxel albumin-stabilized nanoparticle formulation
- paclitaxel-loaded polymeric micelle
- Paget disease of the nipple
- pain threshold
- palliation
- palliative care
- palliative therapy
- palmar-plantar erythrodysesthesia
- palonosetron hydrochloride
- palpable disease
- palpation
- palpitation
- pamidronate
- panic
- papillary tumor
- Paraplatin
- parenteral nutrition
- paroxetine hydrochloride
- PARP
- PARP inhibitor
- partial-breast irradiation
- partial mastectomy
- partial oophorectomy
- partial remission or partial response
- pastoral counselor
- paternal
- pathologic fracture
- pathological stage
- pathological staging
- pathologist
- pathology report
- patient advocate
- Paxil
- peau d'orange
- pedigree
- peer-review process
- peer-reviewed scientific journal
- perfusion magnetic resonance imaging
- perimenopausal
- periodic neutropenia
- perioperative
- peripheral neuropathy
- peripheral venous catheter
- personal health record
- personal medical history
- personalized medicine
- Pertuzumab
- PET scan
- pharmacist
- phase I/II trial
- phase I trial
- phase II/III trial
- phase II trial
- phase III trial
- phase IV trial
- phlebotomy
- photon beam radiation therapy
- phyllodes tumor
- physical examination
- physical therapist
- physical therapy
- physician
- physician assistant
- physiologic
- PI3 kinase inhibitor
- pilocarpine
- pilot study
- placebo
- placebo-controlled
- plastic surgeon
- plastic surgery
- population study
- positive axillary lymph node
- positive test result
- positron emission tomography scan
- post-traumatic stress disorder
- postmenopausal
- postoperative
- postremission therapy
- potentiation
- power of attorney
- PR
- PR+
- PR-
- practitioner
- preauthorization
- precancerous
- preclinical study
- predictive factor
- pregabalin
- premalignant
- premature menopause
- premenopausal
- premium
- prescription
- prevention
- preventive
- preventive mastectomy
- primary care
- primary care doctor
- primary endpoint
- primary therapy
- primary treatment
- primary tumor
- Principal investigator
- prochlorperazine
- progesterone
- progesterone receptor
- progesterone receptor-negative
- progesterone receptor-positive
- progesterone receptor test
- progestin
- prognosis
- prognostic factor
- progression
- progression-free survival
- progressive disease
- Prolia
- proliferative index
- promegapoietin
- prophylactic
- prophylactic mastectomy
- prophylactic oophorectomy
- prophylactic surgery
- prophylaxis
- prospective
- prospective cohort study
- prosthesis
- protective factor
- protein
- protein-bound paclitaxel
- protein expression
- protein expression profile
- protocol
- proton
- proton magnetic resonance spectroscopic imaging
- pruritus
- psychiatrist
- psychological
- psychologist
- psychosocial
- psychotherapy
- PTSD
- pump
- punch biopsy
- qi
- qigong
- quadrantectomy
- quality assurance
- quality of life
- radiation
- radiation brachytherapy
- radiation dermatitis
- radiation fibrosis
- radiation necrosis
- radiation nurse
- radiation oncologist
- radiation physicist
- radiation surgery
- radiation therapist
- radiation therapy
- radical lymph node dissection
- radical mastectomy
- radioactive
- radioactive drug
- radioactive seed
- radioisotope
- radiologic exam
- radiologist
- radiology
- radionuclide
- radionuclide scanning
- radiopharmaceutical
- radiosensitization
- radiosensitizer
- radiosurgery
- radiotherapy
- raloxifene
- raloxifene hydrochloride
- randomization
- randomized clinical trial
- receptor
- RECIST
- reconstructive surgeon
- reconstructive surgery
- recreational therapy
- recurrence
- recurrent cancer